Clinical Significance of the C-Reactive Protein-Triglyceride-Glucose Index in Cardiovascular Disease, Stroke, Cardiovascular-Kidney-Metabolic Syndrome, Cancer, Diabetes, and Osteoporosis: A Narrative Review
Sheng Yang, Xuxin Yao, Jiali Chai, Haoxuan Lu, Wenbin Tang, Ziyi Wu, Wenming He, Yanqing Xie · 2026
Read Clinical Significance of the C-Reactive Protein-Triglyceride-Glucose Index in Cardiovascular Disease, Stroke, Cardiovascular-Kidney-Metabolic Syndrome, Cancer, Diabetes, and Osteoporosis: A Narrative Review by Sheng Yang, Xuxin Yao, Jiali Chai, Haoxuan Lu, Wenbin Tang, Ziyi Wu, Wenming He, Yanqing Xie (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13248966.txt.
Description
Yang and colleagues reviewed a combined blood index across many chronic diseases, in a 2026 narrative review. The index, called CTI, joins C-reactive protein, a marker of inflammation, with a triglyceride-glucose score tied to insulin resistance. It was first proposed in 2022, and the team searched the literature through January 2026 for what it predicts.
Higher CTI tracked consistently with worse risk and outcomes in heart disease, stroke, diabetes, and a combined heart-kidney-metabolic syndrome. Early work also links it to weaker bones, especially in type 2 diabetes. Cut-off values still vary by study, so the authors position CTI as a supporting risk tool, not a diagnosis by itself.
Catalog record
| CREATOR | Sheng Yang, Xuxin Yao, Jiali Chai, Haoxuan Lu, Wenbin Tang, Ziyi Wu, Wenming He, Yanqing Xie |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |